Case Disclosed

President Trump has signaled—often and recently—that he believes drug approval moves too slowly. Meeting with drug manufacturers at the White House on Jan. 31, Trump promised quick yes-or-no approval decisions on new drugs (and stressed the need for lower prices and U.S.-based manufacturing). But the FDA moves fast already— fast enough, say some experts who worry about the standards used to move drugs through review pathways like Priority Review, Breakthrough Therapy, Accelerated Approval, and Fast Track. And when the president pushes for even less rigor, these questions become even more

The Internet has a long memory. When someone objects to material posted online—a critical blog post or a harsh Yelp review, for example—it can be hard to have it removed.